Search Results - Therapeutics

37 Results Sort By:
Monoclonal antibodies against human and mouse leptin for therapeutic and diagonostic use.
BackgroundLeptin is a hormone produced by adipocytes and is elevated in obesity. The congenital lack of leptin results in obesity and the metabolism field widely accepts the concept. Upon cloning of the leptin gene, the original hope was that leptin would act as a break for further food intake and a trigger to increase energy expenditure. The hope was...
Published: 3/5/2020   |   Inventor(s): Zhiqiang An, Philipp Scherer, Ningyan Zhang
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics, Metabolism
Formulation of HDACi Loaded ß-Cyclodextrin-poly (ß-amino ester) Nanoparticles
Researchers have developed a novel formulation strategy to encapsulate molecules, including but not limited to histone deacetylase inhibitor (HDACi) drugs in nanoparticle networks composed of beta-cyclodextrin-poly(beta-amino esters). Advantages of this system include high loading capacity, increased in vivo tolerability, sustained release, and improved...
Published: 1/15/2020   |   Inventor(s): Rachael Sirianni
Keywords(s):  
Category(s): Drug Delivery, Therapeutics, Oncology
Monoclonal antibodies against human endotrophin for therapeutic and diagonostic use.
BackgroundStudies have shown that endotrophin, the carboxy-terminal cleavage product of the COL6α3 chain, has potent effects on transformed mammary ductal epithelial cells in rodents. It is abundantly expressed in adipose tissue and is a chemoattractant for macrophages, exerts effects on endothelial cells and enhances the progression through epithelial-mesenchymal...
Published: 1/10/2020   |   Inventor(s): Zhiqiang An, Ningyan Zhang, Philipp Scherer
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics
HER3 specific monoclonal antibodies for diagnosis and therapeutic use
BackgroundHER-3 is a receptor in the tyrosine kinase family that is a key oncogenic protein in breast cancer as well as other cancers. HER-3 is centrally involved in signaling leading to tumor growth and has been implicated in resistance to cancer treatments, making it an attractive target for cancer therapies.  Several drugs, including some in clinical...
Published: 1/8/2020   |   Inventor(s): Zhiqiang An, Ningyan Zhang
Keywords(s):  
Category(s): Therapeutics, Diagnostics
Improved Antibody-Drug Conjugate Linker Compositions and Methods of Use
Faculty members at the University of Texas Health Science Center at Houston have developed a novel chemical linker for constructing antibody-drug conjugates (ADCs). While traditional ADC linkers can only load a single payload molecule, the developed linker has the ability to load two identical or different drug payloads. Doubling the number of payloads...
Published: 10/17/2019   |   Inventor(s): Kyoji Tsuchikama, Yasuaki Anami, Chisato Tsuchikama, Zhiqiang An, Ningyan Zhang
Keywords(s):  
Category(s): Research Materials, Oncology, Drug Delivery, Therapeutics, Biologics
Methods and composition for novel anti-cancer treatments
Background: The Wnt signaling pathway plays essential roles in development and is frequently hyperactivated in cancer cells as a driving mechanism.  Nearly 90% of colon cancers, for examples are mutated in this pathway. However, direct targeting of this pathway for cancer drug discovery has been challenging due to receptor redundancy and complexity.  ...
Published: 6/26/2019   |   Inventor(s):  
Keywords(s):  
Category(s): Therapeutics, Diagnostics
Methods of X-aptamer generation and compositions thereof
Aptamers are structurally distinct RNA and DNA oligonucleotides (ODNs) that can mimic protein-binding molecules and exhibit high (nM) binding affinity based on their unique secondary three-dimensional structure conformations and not by pair-wise nucleic acid binding. Aptamers can be selected via high-throughput in vitro methods to bind target molecules....
Published: 6/26/2019   |   Inventor(s):  
Keywords(s):  
Category(s): Therapeutics, Diagnostics
Salivary Proline Rich Peptide Decreases Growth of Cancer Cells
Background:Carcinoma of the breast is the second most common type of cancer among women and despite improved early detection, diagnosis and aggressive treatment approaches, consisting of surgery, radiotherapy and/or chemotherapy, carcinoma of the breast is still a great threat to human life. Currently, there is an incomplete knowledge of the molecular...
Published: 8/24/2018   |   Inventor(s):  
Keywords(s):  
Category(s): Oncology, Therapeutics, Biologics
Discovery of Allosteric Non-Covalent KRAS Inhibitors
Activating mutations of KRAS are known to occur in about 25% of all human cancers. Currently, there are no drugs that can directly act on mutated KRAS to stop its cancer causing activities. As a result, KRAS-related cancers, which include some of the deadliest, such as pancreatic cancer, remain untreatable. Finding a direct inhibitor of KRAS remains...
Published: 8/13/2018   |   Inventor(s):  
Keywords(s):  
Category(s): Oncology, Therapeutics, Research Materials
Human Amniotic Fluid Supernatant as a Therapeutic Agent for Hyperproliferative and Inflammatory Skin Conditions.
Keratinocytes are a major cell type in the epidermis. However, keratin proliferation and dysregulation can lead to many keratin associated diseases or disorders, including hyperproliferative skin disorders such as psoriasis, eczema, and keratosis, scaring or suboptimal wound healing. Faculty members at the University of Texas Health Science Center at...
Published: 8/13/2018   |   Inventor(s):  
Keywords(s):  
Category(s): Biologics, Therapeutics
1 2 3 4 
© 2020. All Rights Reserved. Powered by Inteum